Search

Search Results

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1720

  PDF: 1273

  HTML: 397

• RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM

  Ugo Testa, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2023062

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.062

  1288

  PDF: 1089

  HTML: 220

• SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival

  Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Aikaterini Pentidou, Spanoudakis Emmanouil

  e2021006

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.006

  2090

  PDF: 860

  HTML: 262

• PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma

  Ugo Testa; Giuseppe G.M. Leone

  e2025005

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.005

  2515

  HTML: 292

  PDF: 920

• Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio

  Dr. Enrica A. Martino, Dr. G. Mele, Dr. F. Morabito, Dr. M. Gentile, Dr. E. Vigna

  e2025006

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.006

  2227

  PDF: 1639

  HTML: 323

• CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment

  Ugo Testa, Elvira Pelosi, Dr. Germana Castelli

  e2024077

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.077

  1784

  PDF: 871

  HTML: 518

• Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

  Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

  e2025043

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.043

  1221

  PDF: 979

  HTML: 161

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

  Patrizia Tosi, Manuela Imola, Mianulli Anna Maria, Simona Tomassetti, Anna Merli, Annalia Molinari, Serena Mangianti, Marina Ratta, Alessandro Isidori, Giuseppe Visani

  e2012069

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.069

  2591

  PDF: 747

  HTML: 1536

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1594

  PDF: 1408

  HTML: 139

• ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

  Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko

  e2018014

  2018-02-15

  https://doi.org/10.4084/mjhid.2018.014

  5316

  PDF: 1973

  HTML: 1474

• Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES

  Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani

  e2025027

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.027

  1483

  PDF: 1266

  HTML: 324

• "ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

  Benedetto Bruno, Luisa Giaccone, Moreno Festuccia, Mario Boccadoro

  e2010013

  2010-06-01

  https://doi.org/10.4084/mjhid.2010.013

  1479

  PDF: 675

  HTML: 1519

• NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?

  Alessandro Corso, Silvia Mangiacavalli

  e2017053

  2017-08-18

  https://doi.org/10.4084/mjhid.2017.053

  3314

  PDF: 1731

  HTML: 1103

• IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA

  Ugo Testa, Prof. Leone, Dr. Elvira Pelosi, Dr. Germana Castelli, Prof, Valerio De Stefano

  e2024044

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.044

  2601

  PDF: 1186

  HTML: 151

• REAL WORLD MULTIPLE MYELOMA REGISTRY FROM JORDAN, A DEVELOPING COUNTRY.

  Abdalla Awidi, Farah Qasem, A'sem Abu-Qamar, Batool Aqel, Rand Aladayleh, Ilham Alteerah, Ahmad Magableh, , Hisham Bawa”neh, Feras Al-fararjeh

  e2022031

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.031

  1337

  PDF: 754

  HTML: 373

• PLASMA CELL LEUKEMIA UPDATE ON IMMUNOPHENOTYPE, MOLECULAR CHARACTERISTICS, AND THERAPY. The second part of plasma cell neoplasms with spreading in the blood and tissues Plasma Cell Leukemia

  Giuseppe G.M. Leone, Ugo Testa

  e2025080

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.080

  1478

  PDF: 388

  Html: 166

• Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

  Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

  e2025026

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.026

  2024

  PDF: 1701

  HTML: 201

• REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

  Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst

  e2021012

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.012

  1627

  PDF: 648

  HTML: 662

• Flow Cytometry Method as a Diagnostic Tool for Pleural Fluid Involvement in a Patient with Multiple Myeloma

  Muzaffer Keklik, Serdar Sivgin, Cigdem Pala, Celalettin Eroglu, Gulsah Akyol, Leylagul Kaynar, Mustafa Yavuz Koker, Demet Camlica, Ali Unal, Mustafa Cetin, Bulent Eser

  e2012063

  2012-10-03

  https://doi.org/10.4084/mjhid.2012.063

  1472

  PDF: 741

  HTML: 4570

  Figure 1: Chest radiograph: 224

  Figure 2: Flow cytometer analysis of pleural fluid: 194

• COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.

  Monia Marchetti , Robert Peter Gale, Giovanni Barosi

  Page e2021034

  2021-04-29

  https://doi.org/10.4084/MJHID.2021.034

  1499

  PDF: 552

  HTML: 201

• THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT

  Paul Richardson, Jacob Laubach, Anuj Mahindra, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Noopur Raje, Nikhil Munshi, Kenneth Anderson

  e2010009

  2010-05-03

  https://doi.org/10.4084/mjhid.2010.009

  1294

  PDF: 728

  HTML: 623

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2521

  PDF: 803

  HTML: 1743

• QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION

  Alhossain A. Khalafallah, Kristina McDonnell, Hizb U. Dawar, Iain Robertson, David Woods

  e2011057

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.057

  1428

  PDF: 709

  HTML: 1384

  cover letter: 217

• EARLY APPLICATION OF HIGH CUT-OFF HAEMODYALISIS FOR DE-NOVO MYELOMA NEPHROPATHY IS ASSOCIATED WITH LONG-TERM DIALYSIS-INDEPENDENCY AND RENAL RECOVERY

  Alhossain A. Khalafallah, Sie Wuong Loi, Sarah Love, Muhajir B. Mohamed, Rose Mace, Ramy Khalil, Miriam Girgs, Rajesh Raj, Mathew Mathew

  e2013007

  2013-01-02

  https://doi.org/10.4084/mjhid.2013.007

  1400

  PDF: 672

  HTML: 2511

  cover letter: 205

• IMPACT OF QUALITATIVE AND QUANTITATIVE IMMUNOPARESIS ON EARLY INFECTION RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA Immunoparesis and early infection risk in myeloma

  Hongfeng Wang, Jianbin Chen

  e2026062

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.062

  127

  PDF: 328

  HTML: 43

• Brain abscesses caused by Nocardia paucivorans in a multiple myeloma patient treated with lenalidomide and dexamethasone: a case report and review of literature.

  Jacopo Monticelli, Roberto Luzzati, Cristina Maurel, Chiara Rosin, Romina Valentinotti, Claudio Farina

  e2015011

  2014-12-24

  https://doi.org/10.4084/mjhid.2015.011

  1735

  PDF: 1100

  HTML: 6524

  original file with images: 295

• Bilateral Pleural Effusions due to Pulmonary Amyloidosis as the Presenting Manifestation of Multiple Myeloma

  Abhishek Agarwal, Sandeep Singla, Meghana Bansal, Bijay Nair

  e2012010

  2012-01-25

  https://doi.org/10.4084/mjhid.2012.010

  1375

  PDF: 779

  HTML: 4393

  Figure 1: 172

  Untitled: 147

  Untitled: 199

• Successful treatment of gastric relapse in multiple myeloma with bortezomib after autologous hematopoietic stem cell transplantation (autoHSCT)

  Serdar Sivgin

  e2013006

  2013-01-02

  https://doi.org/10.4084/mjhid.2013.006

  1180

  PDF: 643

  HTML: 3263

• LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE

  Patrizia Tosi

  e2013037

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.037

  1350

  PDF: 924

  HTML: 1287

  fig 1A: 196

  figure1B: 171

• SOLITARY PLASMACYTOMA

  Sara Grammatico, Emilia Scalzulli, Maria Teresa Petrucci

  e2017052

  2017-08-23

  https://doi.org/10.4084/mjhid.2017.052

  3988

  PDF: 2228

  HTML: 1253

  fIGURES 1,2: 235

• POOR HEMOPOIETIC STEM CELL MOBILIZERS IN MULTIPLE MYELOMA : A SINGLE INSTITUTION EXPERIENCE

  Guillermo Jose Ruiz-Delgado, Avril Lopez-Otero, Ana Hernandez-Arizpe, Aura Ramirez-Medina, Guillermo Jose Ruiz-Argüelles

  e2010016

  2010-06-19

  https://doi.org/10.4084/mjhid.2010.016

  1201

  PDF: 783

  HTML: 588

• EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?

  Pellegrino Musto, Dr. Nicola Sgherza

  e2024073

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.073

  1576

  PDF: 843

  HTML: 201

• Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments

  NICOLA SGHERZA, Anna Mestice, Angela Maria Vittoria Larocca, Pellegrino Musto

  e2024022

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.022

  785

  PDF: 1169

  HTML: 89

• Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or Treated with Immunomodulatory Agents

  Alhossain A. Khalafallah, Matthias Maiwald, Amanda Cox, Burns Denise, Gerald Bates, Terry Hannan, David Seaton, Bernadene Fernandopulle, Terry Brain

  e2010005

  2010-04-20

  https://doi.org/10.4084/mjhid.2010.005

  1176

  PDF: 579

  HTML: 1150

• An unusual cause of anemia and encephalopathy

  Sanjeev Kumar Sharma, Dharma Choudhary, Anil Handoo, Gaurav Dhamija, Gaurav Kharya, Vipin Khandelwal, Mayank Dhamija, Sweta Kothari

  e2015036

  2015-04-24

  https://doi.org/10.4084/mjhid.2015.036

  4052

  PDF: 877

  HTML: 1521

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1995

  PDF: 1739

  HTML: 922

• Multiple myeloma diagnosed by CT-guided rib biopsy after a hemodilute bone marrow aspirate, in a patient with a biclonal pattern on serum protein electrophoresis Multiple Myeloma diagnosed with CT-guided rib biopsy

  Arjeta Cyrbja, Liri Seraj, Shaqir Qerama

  e2026061

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.061

  199

  PDF: 90

  HTML: 7

• IMPACT OF PRETRANSPLANT DONOR AND RECIPIENT CYTOMEGALOVIRUS SEROSTATUS ON OUTCOME FOR MULTIPLE MYELOMA PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION.

  Jean Elcheikh

  e2013026

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.026

  1332

  PDF: 754

  HTML: 1436

• Molecular Expression of bone marrow angiogenic factors, cell-cell adhesion molecules and matrix-metallo-proteinase plasma cellular disorders: a molecular panel to investigate disease progression

  Maria Cristina Rapanotti

  e2018059

  2018-10-30

  https://doi.org/10.4084/mjhid.2018.059

  1374

  PDF: 780

  HTML: 156

• MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

  Francesca Fazio, Gianfranco Lapietra, Maria Zaira Limongi, Stefania Intoppa, Maria Laura Milani, Alfonso Piciocchi, Maurizio Martelli, Anna Guarini, Robin Foà, Maria Stefania De Propris, Maria Teresa Petrucci

  e2023047

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.047

  1047

  PDF: 738

  HTML: 281

• NEW STRATEGIES FOR STEM CELL MOBILIZATION

  Roberto Lemoli

  e2012066

  2012-10-03

  https://doi.org/10.4084/mjhid.2012.066

  2499

  PDF: 895

  HTML: 2472

• Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis

  Fabiana Gentilini, Anna Levi, Vincenzo Federico, Eleonora Russo, Robin Foà, Maria Teresa Petrucci

  e2012035

  2012-05-07

  https://doi.org/10.4084/mjhid.2012.035

  1601

  PDF: 767

  HTML: 659

• Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET

  Alessandro Gozzetti, Vania Rossi, Alfonso Cerase, Giulia Papini, Marzia Defina, Monica Bocchia

  e2012041

  2012-06-19

  https://doi.org/10.4084/mjhid.2012.041

  1134

  PDF: 764

  HTML: 760

• LIGHT CHAIN AMYLOIDOSIS

  Paolo Milani, Giampaolo Merlini, Giovanni Palladini

  e2018022

  2018-03-01

  https://doi.org/10.4084/mjhid.2018.022

  5924

  PDF: 2368

  HTML: 1344

• FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients

  Paola Stefanoni, Monica Galli, Laura Paris, Alessandro Rambaldi, Nicola Pittalis, Gianluca Cavallaro, Chiara Pavoni

  e2024066

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.066

  1070

  PDF: 638

  Html: 165

• A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab

  Mauro Passucci, Francesca Fazio, Maria Teresa Petrucci

  e2023012

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.012

  1028

  PDF: 970

  HTML: 418

• HEAVY-CHAIN DISEASES AND MYELOMA-ASSOCIATED FANCONI SYNDROME: AN UPDATE

  Roberto Ria, Franco Dammacco, Angelo Vacca

  e2018011

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.011

  5429

  PDF: 1670

  HTML: 1418

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2214

  PDF: 1740

  HTML: 387

• COMPARATIVE EVALUATION OF BONE MARROW ASPIRATE WITH TREPHINE BIOPSY IN HEMATOLOGICAL DISORDERS AND DETERMINATION OF OPTIMUM TREPHINE LENGTH IN LYMPHOMA INFILTRATION

  Surbhi Goyal, Usha Rani Singh, Usha Rusia

  e2014002

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.002

  2067

  PDF: 1087

  HTML: 51814

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS

  Michele Bibas, Shayna Sarosiek, Jorge J. Castillo

  e2024061

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.061

  2966

  PDF: 3284

  HTML: 589